期刊
CANCERS
卷 14, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/cancers14081963
关键词
multiple myeloma; hallmarks of cancer; lncRNA; prognosis; therapy
类别
资金
- INNOLABS-POR Puglia FESR-FSE
- Italian University and Research Ministry [PRIN 20174TB8KW_002]
This article discusses the role of long non-coding RNAs in multiple myeloma, highlighting their regulation of cancer hallmarks and their potential as biomarkers for clinical diagnosis, patient stratification, and therapeutic targeting.
Simple Summary Multiple myeloma (MM) is an aggressive hematological neoplasia caused by the uncontrolled proliferation of aberrant plasmacells. Neoplastic transformation and progression are driven by a number of biological processes, called 'hallmarks of cancer', which are regulated by different molecules, including long non-coding RNAs. A deeper understanding of the mechanisms that regulate MM development and progression will help to improve patients stratification and management, and promote the identification of new therapeutic targets. Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that are not translated into proteins. Nowadays, lncRNAs are gaining importance as key regulators of gene expression and, consequently, of several biological functions in physiological and pathological conditions, including cancer. Here, we point out the role of lncRNAs in the pathogenesis of multiple myeloma (MM). We focus on their ability to regulate the biological processes identified as hallmarks of cancer that enable malignant cell transformation, early tumor onset and progression. The aberrant expression of lncRNAs in MM suggests their potential use as clinical biomarkers for diagnosis, patient stratification, and clinical management. Moreover, they represent ideal candidates for therapeutic targeting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据